Vaxart (NASDAQ: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, announced it will host a conference call on June 11, 2025, at 8:30 AM ET to discuss topline results from its Phase I norovirus trial. The company will release the data before market open. Management will review the data and provide a trial update during the call. Investors can access the webcast through provided links and submit questions in advance to [email protected]. A replay will be available on Vaxart's website after the event.
Vaxart (NASDAQ: VXRT), una societ脿 biotecnologica in fase clinica specializzata nello sviluppo di vaccini orali ricombinanti in forma di pillola, ha annunciato che terr脿 una conference call l'11 giugno 2025 alle 8:30 AM ET per discutere i risultati preliminari del suo trial di Fase I sul norovirus. L'azienda pubblicher脿 i dati prima dell'apertura del mercato. Il management analizzer脿 i dati e fornir脿 un aggiornamento sul trial durante la chiamata. Gli investitori potranno accedere alla webcast tramite i link forniti e inviare domande in anticipo all'indirizzo [email protected]. Una registrazione sar脿 disponibile sul sito web di Vaxart dopo l'evento.
Vaxart (NASDAQ: VXRT), una empresa biotecnol贸gica en etapa cl铆nica que desarrolla vacunas recombinantes orales en forma de pastilla, anunci贸 que realizar谩 una llamada de conferencia el 11 de junio de 2025 a las 8:30 AM ET para discutir los resultados principales de su ensayo de Fase I sobre norovirus. La compa帽铆a publicar谩 los datos antes de la apertura del mercado. La direcci贸n revisar谩 los datos y proporcionar谩 una actualizaci贸n del ensayo durante la llamada. Los inversores podr谩n acceder a la transmisi贸n web a trav茅s de los enlaces proporcionados y enviar preguntas con anticipaci贸n a [email protected]. Una repetici贸n estar谩 disponible en el sitio web de Vaxart despu茅s del evento.
Vaxart (NASDAQ : VXRT), une soci茅t茅 biotechnologique en phase clinique d茅veloppant des vaccins oraux recombinants sous forme de pilule, a annonc茅 qu'elle tiendra une conf茅rence t茅l茅phonique le 11 juin 2025 脿 8h30 (heure de l'Est) pour discuter des r茅sultats principaux de son essai de phase I sur le norovirus. La soci茅t茅 publiera les donn茅es avant l'ouverture du march茅. La direction examinera les donn茅es et fournira une mise 脿 jour de l'essai lors de l'appel. Les investisseurs pourront acc茅der au webcast via les liens fournis et soumettre leurs questions 脿 l'avance 脿 [email protected]. Une rediffusion sera disponible sur le site web de Vaxart apr猫s l'茅v茅nement.
Vaxart (NASDAQ: VXRT), ein biotechnologisches Unternehmen in der klinischen Phase, das orale rekombinante Pillenimpfstoffe entwickelt, gab bekannt, dass es am 11. Juni 2025 um 8:30 Uhr ET eine Telefonkonferenz abhalten wird, um die wichtigsten Ergebnisse seiner Phase-I-Studie zum Norovirus zu besprechen. Das Unternehmen wird die Daten vor Markter枚ffnung ver枚ffentlichen. Das Management wird die Daten w盲hrend des Anrufs 眉berpr眉fen und ein Update zur Studie geben. Investoren k枚nnen 眉ber bereitgestellte Links auf das Webcast zugreifen und Fragen im Voraus an [email protected] senden. Eine Aufzeichnung wird nach der Veranstaltung auf der Website von Vaxart verf眉gbar sein.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update.
The conference call can be accessed using the following information:
奥别产肠补蝉迟:听 Date:聽Wednesday, June 11, 2025聽鈥撀�8:30 a.m. ET Domestic: (877) 407-0832 International: (201) 689-8433 Conference ID: 13754315
Investors may submit written questions in advance of the conference call to .
A replay of the webcast will be available on the Company鈥檚 website at following the conclusion of the event.
About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart鈥檚 development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart鈥檚 first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
This press release was published by a CLEAR庐 Verified individual.
FAQ
When will Vaxart (VXRT) release its Phase I norovirus trial results?
Vaxart will release the topline data before market open on Wednesday, June 11, 2025.
How can investors access Vaxart's norovirus trial results conference call?
Investors can access the call on June 11, 2025, at 8:30 AM ET via domestic line (877) 407-0832, international line (201) 689-8433, or webcast with Conference ID: 13754315.
What type of vaccine technology is Vaxart (VXRT) developing?
Vaxart is developing oral recombinant pill vaccines based on its proprietary delivery platform.
Can investors submit questions for Vaxart's conference call?
Yes, investors can submit written questions in advance of the conference call by emailing [email protected].
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
